The efficacy of osimertinib was demonstrated in the AURA3 trial, which was conducted in NSCLC patients with advanced progression following first-line EGFR-TKI therapy due to the becoming positive for the T790M mutation in EGFR [27]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.